Given these findings, the DHA–FFAR4 pathway offers potential for improving orthodontic treatments, particularly for patients prone to increased inflammation and reduced bone remodeling, such as those with age-related inflammatory disorders, obesity, or metabolic syndromes. The gene discussed is FFAR4; the disease is obesity due to melanocortin 4 receptor deficiency.